Japan Medical Association Explains Outline of FY2026 Medical Fee Revision and Seeks Cooperation for Dissemination

News Highlights

The Japan Medical Association is explaining the outline of the FY2026 medical fee revision and requesting cooperation from its members for dissemination. As the revision directly impacts the management of medical institutions, early understanding and response are essential. In particular, the importance of mid- to long-term management strategies, including M&A and business succession, is suggested, such as maintaining facility standards, distributing the burden of capital investment, and utilizing tax incentives by transitioning to specific medical corporations or social medical corporations.

M&A Medical Editorial Department’s Perspective

The explanation of the FY2026 medical fee revision outline is more than just a notification of system changes for medical institution managers. This initiative led by the Japan Medical Association strongly suggests the necessity of mid- to long-term management strategies that consider the revision cycle, especially strategic planning integrated with business succession. For example, maintaining and strengthening facility standards can make group affiliation a realistic option for small medical institutions that find it difficult to do so independently, allowing them to benefit from economies of scale. Furthermore, considering tax schemes with a view to transitioning to specific medical corporations or social medical corporations not only reduces tax burdens at the time of succession but also affects future business continuity. The outline of this revision will serve as an opportunity to accelerate these strategic considerations.

Points Raised by This News

• The FY2026 revision will be a cornerstone for mid- to long-term management and succession strategies, not just a single-year event.
• To maintain facility standards and distribute capital investment burdens, leveraging economies of scale through group affiliation is realistic.
• Utilizing tax incentives by transitioning to specific medical corporations or social medical corporations contributes to reducing tax burdens during succession.
• The Japan Medical Association’s proactive dissemination aims to promote early understanding of the revision’s content and facilitate strategic planning.

Practical Questions Arising from This News

• Which medical specialties will be particularly affected by this revision?
• What specific facility standards can be maintained or strengthened through group affiliation?
• What level of tax incentives can be expected by transitioning to specific medical corporations or social medical corporations?

If You Feel “Should I Consult Too?”

If you feel that now is the time to specifically consider your institution’s management strategy and future business succession after receiving the explanation of the FY2026 medical fee revision outline, please consult with M&A intermediary specialists. It is particularly important to understand concrete options, including group affiliation and changes in corporate status, along with their merits and demerits, for challenges that are difficult to address independently, such as maintaining facility standards, capital investment, and tax schemes.

M&A Medical (CentralMedience Inc.) supports the business succession of medical corporations, hospitals, and clinics with a complete success fee system as an M&A support institution certified by the Small and Medium Enterprise Agency. Consultations are accepted with strict confidentiality. Free consultation here